PharmTech Drug Digest 11.20
News|Articles|July 29, 2014

Redbiotec Collaborates with GE Healthcare Life Sciences on Vaccine Development and Manufacturing

Redbiotec and GE Healthcare Life Sciences develop a novel manufacturing process for virus-like particles.

Redbiotec, a Swiss biopharmaceutical company specializing in vaccine development, is collaborating with GE Healthcare Life Sciences to develop and produce vaccines against cytomegalovirus (CMV), a common virus in the herpes family of viruses. Using GE Healthcare's single-use WAVE Bioreactor and ReadyToProcess crossflow filtration system, the team developed a novel process for the production, clarification, and concentration of CMV-like particles.

Redbiotec uses its proprietary rePAX co-expression technology for the efficient generation of multi-component virus-like particles (VLPs) and other protein assemblies. This technology is used to support the company’s mission to discover and develop vaccines against the highly prevalent influenza and herpes viruses.

Source: Redbiotec


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.